Global Human Insulin Market 2018-2024

  • Product Code:
    RP-ID-10078052
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    77
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Human Insulin Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Insulin is a peptide hormone that helps in controlling the absorption of fat and carbohydrate in the body. The human insulin market is anticipated to grow at a robust CAGR during the forecast period due to a high incidence rate of diabetes, globally.
The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin.
Market Analysis: The “Global Human Insulin” market is estimated to witness a CAGR of 10.2% during the forecast period 2017–2023. The human insulin market is analyzed based on three segments – top insulin brands, product types, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global human insulin market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market.
Top Insulin Brands: Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus.
Key Players: Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.
Competitive Analysis: Regardless of the size of the total market, it is chiefly dominated by Novo Nordisk, Sanofi, and Eli Lilly. These firms function globally either independently or through subsidiaries and distributors. The insulin products of Novo Nordisk are sold in 111 countries along with 101 countries for Sanofi’s insulin products and 94 countries for Eli Lilly’s insulin products. Especially in higher income countries of Western Europe, nearly 55% of insulin products are sold by these major manufacturers. Moreover, in 2012, they occupied 88.7% of share in the global insulin market. However, there are many small companies involved in the production and sales of insulin products. Other major companies in the market are Wockhardt, Biocon, Julphar, Oramed, GSK, and SemBioSys Genetics Inc.
Benefits: The report provides complete details about the usage and adoption rate of human insulin in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 8
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Segmented Addressable Market (SAM) 13
3.2.1 Trends of Human Insulin market 14
3.3 Related Markets 15
3.3.1 Oncology (Cancer) Drugs 15
3.3.2 Active pharmaceutical ingredients (APIs) 16
3.3.3 Over the counter drugs (OTC) 16
3.3.4 Diabetes Drugs 17
4 Market Outline 18
4.1 Pipeline products 18
4.2 Market Segmentation 18
4.3 Porter 5(Five) Forces 19
4.4 PEST Analysis 20
5 Market Characteristics 21
5.1 Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Increasing Aging Population 22
5.1.1.2 Increasing People Suffering with Diabetes 24
5.1.2 Opportunities 24
5.1.2.1 Increase healthcare spending 24
5.1.2.2 Patent Expiry for Blockbuster Drugs 25
5.1.3 Restraints 25
5.1.3.1 Complex regulatory process 25
5.1.3.2 High cost of insulin 25
5.1.4 DRO – Impact Analysis 27
5.1.5 Key Stakeholders 28
6 Insulin Types: Market Size and Analysis 29
6.1 Overview 29
6.2 Lantus 29
6.3 Humulin 29
6.4 Levemir 30
6.5 Humalog 30
6.6 NovoLog/NovoRapid 30
6.7 Tresiba 31
6.8 Basaglar/ Abasaglar 31
6.9 Toujeo 31
6.10 Apidra 32
Company: Sanofi 32
7 Types: Market Size and Analysis 33
7.1 Overview 33
7.2 Modern Insulin 34
7.2.1 Rapid Acting Insulin Analogs 34
7.2.2 Premixed analogue insulins 34
7.2.3 Long-acting insulin 34
7.3 Traditional Human Insulin 35
7.3.1 Regular Human Insulin 35
7.3.2 NPH Human Insulin 36
7.3.3 Pre-Mixed Insulin 36
8 Regions: Market Size and Analysis 37
8.1 Overview 37
8.2 North America 39
8.2.1 Overview 39
8.2.2 United States 40
8.2.3 Canada 41
8.3 Europe 41
8.3.1 Overview 41
8.3.2 United Kingdom 42
8.3.3 Germany 42
8.4 APAC 43
8.4.1 Overview 43
8.4.2 India 43
8.4.3 China 44
8.4.4 Japan 44
8.5 Rest of the World 45
8.5.1 Overview 45
8.5.2 Middle East and Africa 46
8.5.3 Brazil 46
9 Competitive Landscape 47
10 Vendor Profiles 50
10.1 Novo Nordisk A/S 50
10.1.1 Overview 50
10.1.2 Geographic Revenue 52
10.1.3 Business Focus 52
10.1.4 SWOT Analysis 53
10.1.5 Business Strategy 53
10.2 Sanofi 54
10.2.1 Overview 54
10.2.2 Geographic Revenue 57
10.2.3 Business Focus 57
10.2.4 SWOT Analysis 58
10.2.5 Business Strategy 58
10.3 Eli Lilly & Company Ltd 59
10.3.1 Overview 59
10.3.2 Business Focus 62
10.3.3 SWOT Analysis 63
10.3.4 Business Strategies 63
10.4 Astra Zenca PLC. 64
10.4.1 Overview 64
10.4.2 Geographic Presence 68
10.4.3 Business Focus 68
10.4.4 SWOT Analysis 69
10.4.5 Business Strategy 69
11 Companies to Watch For 70
11.1 GlaxoSmithKline plc 70
11.1.1 Overview 70
11.2 Julphar Gulf Pharmaceutical Industries. 71
11.2.1 Overview 71
11.2.2 Highlights 72
11.3 Biocon Ltd 72
11.3.1 Overview 72
11.4 Wockhardt 74
11.4.1 Overview 74
11.4.2 Highlights 74
11.5 Oramed 74
11.5.1 Overview 74
11.5.2 Highlights 75
11.6 SemBioSys Genetics Inc. 75
11.6.1 Overview 75
Annexure 76
Abbreviations 76

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports